A number of firms have modified their ratings and price targets on shares of Johnson & Johnson (NYSE: JNJ) recently:

  • 2/5/2018 – Johnson & Johnson was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $152.28 price target on the stock.
  • 1/24/2018 – Johnson & Johnson had its price target raised by analysts at Stifel Nicolaus from $142.00 to $145.00. They now have a “hold” rating on the stock.
  • 1/24/2018 – Johnson & Johnson had its “sell” rating reaffirmed by analysts at BTIG Research. They now have a $110.00 price target on the stock. They wrote, “Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT.   We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report).   Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17.””
  • 1/23/2018 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $152.28 price target on the stock.
  • 1/22/2018 – Johnson & Johnson was given a new $154.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 1/12/2018 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $160.00 price target on the stock, up previously from $155.00.
  • 1/11/2018 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $150.89 price target on the stock.
  • 1/9/2018 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Royal Bank of Canada.
  • 1/8/2018 – Johnson & Johnson was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $147.40 price target on the stock.
  • 1/2/2018 – Johnson & Johnson was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.
  • 1/1/2018 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $147.40 price target on the stock.
  • 12/22/2017 – Johnson & Johnson was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $146.35 price target on the stock.
  • 12/20/2017 – Johnson & Johnson was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $147.14 price target on the stock.

Shares of Johnson & Johnson (JNJ) opened at $129.53 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52-week low of $114.23 and a 52-week high of $148.32. The company has a market capitalization of $347,984.94, a PE ratio of 332.13, a PEG ratio of 2.33 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the previous year, the firm earned $1.58 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. research analysts forecast that Johnson & Johnson will post 8.08 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 861.54%.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.